Lung Cancer Clinical Trials

SMALL CELL
Alliance-A151216: Adjuvant Lung Cancer enrichment marker identification and sequencing trial (Alchemist) The purpose of the study is to examine lung cancer patients’ surgically removed tumors for certain genetic changes and to possibly refer these patients to a treatment study with the drugs that may specifically target tumors that have the genetic changes. Learn more about Alliance-A151216 trial or contact the Reading Hospital Protocol Office at 484-628-8193.
A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) Learn more about Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) or contact the Pottstown Hospital Clinical Research Office at 610-327-7544.
SWOG S1827 / MAVERICK: MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer. The purpose of this study is to compare the effects of using brain MRIs alone versus brain MRIs plus PCI on the lifespan of patients with small cell lung cancer. Learn more about the SWOG S1827/MAVERICK trial or call the Reading Hospital Protocol Office at 484-628-8193.

SMALL CELL

Alliance-A151216: Adjuvant Lung Cancer enrichment marker identification and sequencing trial (Alchemist)

The purpose of the study is to examine lung cancer patients’ surgically removed tumors for certain genetic changes and to possibly refer these patients to a treatment study with the drugs that may specifically target tumors that have the genetic changes.

Learn more about Alliance-A151216 trial or contact the Reading Hospital Protocol Office at 484-628-8193.

A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Learn more about Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) or contact the Pottstown Hospital Clinical Research Office at 610-327-7544.

SWOG S1827 / MAVERICK: MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer.

The purpose of this study is to compare the effects of using brain MRIs alone versus brain MRIs plus PCI on the lifespan of patients with small cell lung cancer.

Learn more about the SWOG S1827/MAVERICK trial or call the Reading Hospital Protocol Office at 484-628-8193.

NON-SMALL CELL
NRG-LU008: Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy (SBRT) Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer. The purpose of this study is to compare the usual treatment alone to using SBRT plus the usual treatment. Learn more about the NRG-LU008 trial or call the Reading Hospital Protocol Office at 484-628-8193.
ECOG/ACRIN E4512: Crizotinib in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and ALK fusion mutations (an Alchemist Treatment Trial) The purpose of this study is to compare any good and bad effects of using the study drug, crizotinib (also known as Xalkori), after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer. Learn more about ECOG/ACRIN E4512 trial or contact the Reading Hospital Protocol Office at 484-628-8193
E4512: A Phase III Double-Blind Trial of Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein Learn more about Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) or contact the Pottstown Hospital Clinical Research Office at 610-327-7544.
EA5163: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis Learn more about Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer or contact the Pottstown Hospital Clinical Research Office at 610-327-7544.
EA5181: Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC Learn more about Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer or contact the Pottstown Hospital Clinical Research Office at 610-327-7544.
Alliance-A081801: Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO. The purpose of this study is to compare the usual treatment alone to using pembrolizumab plus the usual treatment. Learn more about the Alliance-A081801 trial or call the Reading Hospital Protocol Office at 484-628-8193.
A081801: Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO Learn more about Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study or contact the Pottstown Hospital Clinical Research Office at 610-327-7544.
S1714: Neuropathy Trial (Observational Study) Eligibility: Stg I,II or III primary non-small cell lung cancer, breast cancer or ovarian/fallopian tube cancer. Scheduled to receive taxane-based chemotherapy. The purpose of this study is to develop and validate a prediction model of peripheral neuropathy in patients receiving taxane-based chemotherapy regimens. Learn more about the S1714 trail.
LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (LungMAP Screening Study) Learn more about Lung-MAP: A Master Screening Protocol for PreviouslyTreated Non-Small Cell Lung Cancer or contact the Pottstown Hospital Clinical Research Office.
S1900E: A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (LUNG MAP Sub Study) Learn More: Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG-S1914: A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early-Stage NSLC. The purpose of this study is to compare the usual radiation treatment alone to using the immunotherapy drug atezolizumab plus the usual radiation treatment to treat early-stage non-small cell lung cancer (NSCLC). Learn more about the SWOG-S1914 trial or call the Reading Hospital Protocol Office at 484-628-8193.

NON-SMALL CELL

NRG-LU008: Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy (SBRT) Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer.

The purpose of this study is to compare the usual treatment alone to using SBRT plus the usual treatment.

Learn more about the NRG-LU008 trial or call the Reading Hospital Protocol Office at 484-628-8193.

ECOG/ACRIN E4512: Crizotinib in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and ALK fusion mutations (an Alchemist Treatment Trial)

The purpose of this study is to compare any good and bad effects of using the study drug, crizotinib (also known as Xalkori), after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer.

Learn more about ECOG/ACRIN E4512 trial or contact the Reading Hospital Protocol Office at 484-628-8193

E4512: A Phase III Double-Blind Trial of Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Learn more about Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) or contact the Pottstown Hospital Clinical Research Office at 610-327-7544.

EA5163: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis

Learn more about Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer or contact the Pottstown Hospital Clinical Research Office at 610-327-7544.

EA5181: Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Learn more about Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer or contact the Pottstown Hospital Clinical Research Office at 610-327-7544.

Alliance-A081801: Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO.

The purpose of this study is to compare the usual treatment alone to using pembrolizumab plus the usual treatment.

Learn more about the Alliance-A081801 trial or call the Reading Hospital Protocol Office at 484-628-8193.

A081801: Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

Learn more about Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study or contact the Pottstown Hospital Clinical Research Office at 610-327-7544.

S1714: Neuropathy Trial (Observational Study)

Eligibility: Stg I,II or III primary non-small cell lung cancer, breast cancer or ovarian/fallopian tube cancer. Scheduled to receive taxane-based chemotherapy.

The purpose of this study is to develop and validate a prediction model of peripheral neuropathy in patients receiving taxane-based chemotherapy regimens.

Learn more about the S1714 trail.

LUNGMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (LungMAP Screening Study)

Learn more about Lung-MAP: A Master Screening Protocol for PreviouslyTreated Non-Small Cell Lung Cancer or contact the Pottstown Hospital Clinical Research Office.

S1900E: A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (LUNG MAP Sub Study)

Learn More: Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

SWOG-S1914: A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early-Stage NSLC.

The purpose of this study is to compare the usual radiation treatment alone to using the immunotherapy drug atezolizumab plus the usual radiation treatment to treat early-stage non-small cell lung cancer (NSCLC).

Learn more about the SWOG-S1914 trial or call the Reading Hospital Protocol Office at 484-628-8193.

LUNG CANCER SCREENING
Lighthouse: Peripheral blood samples will be collected from individuals who have a planned lung cancer screening by LDCT and meet the protocol eligibility criteria. The blood samples and subject data will be used in Roche-sponsored studies for the development of cancer screening and detection products. Principal Investigator: Brian Kane Sponsor: Roche To learn more about the Lighthouse - Lung Cancer Screening trial, call the Reading Hospital Protocol Office at 484-628-8193.

LUNG CANCER SCREENING

Lighthouse: Peripheral blood samples will be collected from individuals who have a planned lung cancer screening by LDCT and meet the protocol eligibility criteria. The blood samples and subject data will be used in Roche-sponsored studies for the development of cancer screening and detection products.

Principal Investigator: Brian Kane

Sponsor: Roche

To learn more about the Lighthouse - Lung Cancer Screening trial, call the Reading Hospital Protocol Office at 484-628-8193.